Dual-Purpose Intervention
Many patients with primary liver cancer in China carry chronic hepatitis B (HBV) infection, which drives both cirrhosis and hepatocarcinogenesis. Treating the tumor without addressing HBV leaves the underlying disease process active.
UMIPIC's intratumoral immune activation extends beyond the injected lesion: in documented cases, patients with chronic HBV-related cirrhosis and single or multifocal hepatocellular carcinoma achieved both tumor control and durable HBV seroconversion to negative.
This is a pipeline extension of our core sustained-release immunotherapy platform — targeting chronic hepatitis B cirrhosis reversal and HBV-negative conversion alongside liver cancer treatment.
